Abstract
Purpose
We aimed to explore whether insomnia modifies the relationship between insulin resistance (IR) and incident hypertension (HTN) over a 6-year longitudinal period.
Methods
To explore the longitudinal relationship between IR, insomnia, and HTN, we included data from 3300 participants over a 6-year follow-up period in a large Hispanic/Latino cohort. IR was defined using the Youden index to select the optimal homeostasis model assessment of insulin resistance cut‑point based on ROC curve analysis, while insomnia was assessed using the Women’s Health Initiative Insomnia Rating Scale. Cox regression analysis was performed to assess the relationship between IR, insomnia and incident HTN.
Results
We found neither IR nor insomnia alone was associated with incident HTN, whereas IR combined with insomnia increased the risk of HTN by 39% (HR, 1.39; 95% CI, 1.05–1.85) after adjustment for potential confounders. Meanwhile, a significant interaction between IR and insomnia was observed (P = 0.045). Post-estimation linear combination analyses showed that IR was associated with a 60% higher risk of incident HTN among participants with insomnia (HR, 1.60; 95% CI, 1.16–2.21), but not among those without insomnia. Moreover, this synergistic association was significantly associated with incident HTN among men and participants younger than 42 years.
Conclusion
This large, longitudinal study identified a significant longitudinal relationship that IR was associated with a higher HTN risk only among participants with insomnia, suggesting that coexisting insomnia may identify a subgroup particularly susceptible to hypertension.
Keywords: insulin resistance, insomnia, hypertension, hispanic/latino
Plain Language Summary
Insulin resistance occurs when the body does not respond effectively to insulin and may increase the likelihood of developing high blood pressure. Insomnia has also been linked to cardiovascular and metabolic problems, but it remains unclear whether insomnia makes people with insulin resistance more susceptible to hypertension. We analyzed data from 3,300 Hispanic and Latino adults who were followed for approximately 6 years. Insulin resistance alone was not associated with a significantly higher risk of hypertension. However, among participants with insomnia, insulin resistance was associated with a 60% higher risk of developing hypertension. These findings suggest that people with both insulin resistance and insomnia may represent a subgroup at increased risk of hypertension. Further studies are needed to confirm these findings and determine whether improving sleep can help reduce this risk.
Introduction
Hypertension (HTN) is one of the most prevalent cardiometabolic diseases among adults in the United States, imposing a significant public health challenge and substantial burden. According to a previous study using the most recent 2017 definition, the age-adjusted prevalence of HTN among US adults aged ≥20 years was estimated at 46.7% (50.4% in men and 43.0% in women) based on data from the 2017–2020 National Health and Nutrition Examination Survey (NHANES).1 Notably, among racial/ethnic subgroups, the HTN control rate in Hispanic/Latino patients is significantly lower than that in non-Hispanic White patients.2 This population-specific gap in disease control not only exacerbates health inequities but also highlights the need for more targeted etiological and intervention studies focused on this group.
Insulin resistance (IR) is a core pathophysiological basis of modern metabolic diseases. It is defined physiologically as a state in which target tissues exhibit reduced responsiveness to physiological insulin levels and is considered a pathogenic driver of many metabolic and cardiovascular diseases, including metabolic syndrome, nonalcoholic fatty liver disease, atherosclerosis, and type 2 diabetes mellitus.3 Beyond its metabolic consequences, IR can also regulate blood pressure through several pathways. On the one hand, it activates the renin-angiotensin-aldosterone system to disrupt renal water and sodium balance; on the other hand, it interferes with the normal regulatory function of the sympathetic nervous system, ultimately inducing or exacerbating HTN.4,5 Existing cross-sectional and longitudinal studies have consistently confirmed the association between IR and HTN.6–8 For example, IR has been associated with higher systolic blood pressure (SBP) and diastolic blood pressure (DBP) in Hispanic/Latino populations9 and with stage I isolated diastolic HTN in Taiwanese military personnel over a median 6-year follow-up.10 Mendelian randomization study further supports the conclusion that genetically determined IR increases the risk of HTN.11 However, there are some limitations in current research. First, the most commonly used and easily operable indicators for assessing IR in clinical practice are the HOMA-IR and the Triglyceride-Glucose (TyG) index.12 Nevertheless, studies investigating the association between IR and HTN based on HOMA-IR remain scarce. Second, research targeting the Hispanic population is particularly insufficient, and the causal mechanism linking IR to the development of HTN in this group has not been clarified, failing to provide mechanistic evidence support for HTN prevention and control in this population.9
Insomnia, one of the most prevalent sleep disorders, has been consistently associated with HTN.13–15 The underlying mechanisms primarily involve metabolic and endocrine imbalances caused by sleep disturbances. Insomnia can inhibit insulin secretion, activate the hypothalamic-pituitary-adrenal axis, and increase the release of inflammatory factors, leading to disruptions in blood pressure regulation mechanisms and ultimately raising the risk of HTN.16,17 Meanwhile, there is also a close association between insomnia and IR. Previous studies have demonstrated an association between insomnia symptoms and increased IR.18–20 However, whether insomnia modifies the association between IR and incident HTN has not been systematically examined. To our knowledge, no longitudinal study has specifically examined whether insomnia modifies the association between HOMA-IR-defined IR and incident HTN in Hispanic/Latino adults. Using the same underlying Hispanic Community Health Study/Study of Latinos (HCHS/SOL) cohort, our previous study found that insomnia, when comorbid with sleep-disordered breathing, was associated with an increased risk of incident metabolic syndrome.21 Together with previous evidence linking insomnia to incident hypertension, this finding provides a rationale for examining whether insomnia modifies the association between IR and incident HTN. In the present study, we further focused on IR and incident HTN, formally evaluated insomnia as an effect modifier, and excluded participants with sleep-disordered breathing.
Therefore, using data from the HCHS/SOL, the largest community-based cohort of Hispanic/Latino adults in the United States, we examined the longitudinal associations of IR and insomnia with incident HTN over a 6-year period and assessed whether insomnia modified the association between IR and incident HTN.
Methods
Study Population
Our study utilized a sample from the HCHS/SOL main study, consisting of 12,647 participants at Visit 1 and 8816 participants at Visit 2. Both the structure and execution of this investigation have been published and approved by the institutional ethics committees of the involved organizations.22,23
We first excluded individuals who missed visit 2, resulting in 8816 participants. Next, we excluded those with baseline HTN (N=2,911), baseline HTN medication (N=94), baseline diabetes (N=666), a history of heart failure (N=38), a history of coronary heart disease (N=162), and an apnea–hypopnea index (AHI) ≥5 events/hour (N=1,473). Additionally, we excluded participants with missing data for AHI (N=83), WHIIRS (N=34) and covariates (N=55), leaving a final analytic sample of 3300 participants (Figure 1).
Figure 1.

Sample flow chart.
During the first visit, participants were assessed using questionnaires for sleep symptoms, social demographics, and physical activity. Sleep-disordered breathing was assessed using the Apnea Risk Evaluation System (ARES), a portable sleep-monitoring device.24 The AHI was derived from ARES recordings and scored by trained personnel at a central sleep reading center who were blinded to other study data. In the present study, AHI was used to exclude participants with sleep-disordered breathing (AHI ≥5 events/hour); participants with missing AHI data were also excluded. Blood and urine samples were collected each study site according to standardized procedures and sent daily to the central laboratory for analysis. The details of the tests can be found in previously published research.22 Every participant provided written consent prior to their involvement in the study.
Hypertension
HTN was defined as an SBP ≥ 140 mm Hg, a DBP ≥ 90 mm Hg, or self-reported use of antihypertensive medication. Incident HTN was defined as new-onset HTN at Visit 2 among participants who were free of HTN at baseline. Blood pressure was measured on the right arm (brachial artery) using an automatic sphygmomanometer (Omron model HEM-907XL) in a seated position after a 5-minute quiet rest. Three measurements 1 minute apart were obtained and averaged.
Insulin Resistance
IR was assessed using the HOMA-IR, a widely employed and validated surrogate marker strongly correlated with the hyperinsulinemic-euglycemic clamp (HEC), the gold standard method for assessing IR.12 To accurately establish this threshold, a reference group comprising 774 healthy individuals was selected, with participants rigorously defined as free from metabolic abnormalities. Specifically, in this study these individuals had none of the following metabolic abnormalities: elevated blood pressure (defined as an average SBP ≥130 mmHg, an average DBP ≥85 mmHg, or self-reported antihypertensive medication use; averages derived from three measurements), elevated fasting glucose (≥100 mg/dL or self-reported use of antidiabetic medications), elevated triglycerides (≥150 mg/dL), reduced high-density lipoprotein (HDL) cholesterol levels (<40 mg/dL for men or <50 mg/dL for women), or increased waist circumference (≥102 cm for men or ≥88 cm for women). The remaining participants, who had one or more metabolic abnormalities, comprised the comparison group. ROC curve analysis was performed, and the optimal HOMA-IR cut-off was selected by maximizing the Youden index,12,25 yielding a threshold of 1.77 (AUC=0.70, sensitivity=0.68, specificity=0.72).
Insomnia
Insomnia symptoms were assessed using the Women’s Health Initiative Insomnia Rating Scale (WHIIRS), a standardized self-report instrument developed and validated in a racially and ethnically diverse population.26,27 The WHIIRS consists of four items that ask how often, during the past 4 weeks, participants (1) had difficulty falling asleep, (2) woke up several times during the night, (3) woke up earlier than intended, and (4) had trouble going back to sleep after waking up too early. The fifth item asks participants to rate their overall typical night’s sleep. Each item is rated on a 5-point Likert scale, yielding a total score from 0 to 20, with higher scores indicating more severe insomnia symptoms. In line with previous studies, we defined insomnia as a total WHIIRS score of ≥ 9.
Covariates
We adjusted for sociodemographic factors, including age, sex, education, and ethnicity; adiposity-related factors, including body mass index (BMI) and waist circumference; and health behaviors, including alcohol consumption, cigarette smoking, and physical activity level. Physical activity was assessed using a modified self-reported version of the Global Physical Activity Questionnaire, developed by the World Health Organization (WHO).28 The questionnaire collected information on physical activity participation in three settings (work, travel, and leisure) and sedentary behavior. We also adjusted for baseline SBP and DBP given that baseline blood pressure is one of the strongest predictors of incident HTN.
Statistical Analysis
The sample characteristics are presented in Table 1, with categorical variables summarized as numbers and percentages and continuous variables as means and standard deviations. Participants were classified into four groups including control (without IR or insomnia), IR, insomnia and comorbid of IR and insomnia. Group differences were analyzed using the Chi-squared test for categorical variables or the Kruskal–Wallis test for continuous variables.
Table 1.
HCHS/SOL Sample Characteristics
| Control | Insulin Resistance | Insomnia | Comorbidity | P | ||
|---|---|---|---|---|---|---|
| Subject, % (n) | 28.2 (932) | 39.1 (1289) | 13.3 (439) | 19.4 (640) | ||
| Age, y | 40.2 ± 12.5 | 38.4 ± 12.5 | 43.1 ± 12.1 | 42.1 ± 12.1 | < 0.001 | |
| Sex, % (n) | < 0.001 | |||||
| Women | 62.8 (585) | 66.3 (854) | 68.3 (300) | 75.8 (485) | ||
| Men | 37.2 (347) | 33.7 (435) | 31.7 (139) | 24.2 (155) | ||
| Incident Hypertension, % (n) | 9.9 (92) | 13.4 (173) | 14.1 (62) | 19.7 (126) | < 0.001 | |
| HOMA-IR | 1.2 ± 0.4 | 3.6 ± 2.3 | 1.2 ± 0.4 | 3.5 ± 2.1 | < 0.001 | |
| BMI, kg/m2 | 25.5 ± 3.7 | 29.9 ± 5.2 | 26.2 ± 4.2 | 30.1 ± 5.3 | < 0.001 | |
| Alcohol use, % (n) | 0.032 | |||||
| Never | 20.2 (188) | 21.5 (277) | 15.9 (70) | 15.6 (100) | ||
| Former | 27.8 (259) | 30.8 (397) | 29.8 (131) | 34.8 (223) | ||
| Current | 52.0 (485) | 47.7 (615) | 54.2 (238) | 49.5 (317) | ||
| Cigarette use, % (n) | 0.009 | |||||
| Never | 69.3 (646) | 70.4 (907) | 56.7 (249) | 61.4 (393) | ||
| Former | 14.4 (134) | 14.0 (180) | 13.2 (58) | 19.8 (127) | ||
| Current | 16.3 (152) | 15.7 (202) | 30.1 (132) | 18.8 (120) | ||
| Education, % (n) | 0.873 | |||||
| Less Than HS | 30.5 (284) | 29.9 (385) | 29.2 (142) | 34.5 (221) | ||
| HS or Equivalent | 27.3 (254) | 27.7 (357) | 29.2 (128) | 29.8 (191) | ||
| Greater than HS or Equivalent | 42.3 (394) | 42.4 (547) | 38.5 (169) | 35.6 (228) | ||
| Ethnic, % (n) | < 0.001 | |||||
| Dominican | 10.4 (97) | 7.0 (90) | 13.2 (58) | 9.1 (58) | ||
| Central American | 9.4 (88) | 12.5 (161) | 9.1 (40) | 10.2 (65) | ||
| Cuban | 10.5 (98) | 12.1 (156) | 15.0 (66) | 14.4 (92) | ||
| Mexican | 46.7 (435) | 48.3 (623) | 32.6 (143) | 39.4 (252) | ||
| Puerto Rican | 11.7 (109) | 8.7 (112) | 20.7 (91) | 17.8 (114) | ||
| South American | 8.8 (82) | 8.8 (114) | 6.4 (28) | 6.7 (43) | ||
| More than one/Other heritage | 2.5 (23) | 2.6 (33) | 3.0 (13) | 2.5 (16) | ||
| Time between visits, y | 6.1 ± 0.8 | 6.1 ± 0.8 | 6.1 ± 0.9 | 6.1 ± 0.8 | 0.482 | |
| Fasting Glucose, mmol/L | ||||||
| Glucose V1 | 89.7 ± 6.9 | 94.3 ± 7.7 | 89.7 ± 6.7 | 94.5 ± 8.3 | < 0.001 | |
| Glucose V2 | 94.0 ± 13.9 | 98.8 ± 15.5 | 93.9 ± 8.6 | 100.5 ± 22.3 | < 0.001 | |
| BP, mmHg | ||||||
| SBP V1 | 112.0 ± 11.7 | 113.7 ± 11.4 | 112.5 ± 11.5 | 114.6 ± 11.3 | < 0.001 | |
| DBP V1 | 66.7 ± 8.8 | 69.8 ± 8.4 | 68.2 ± 8.5 | 70.8 ± 8.0 | < 0.001 | |
| SBP V2 | 114.3 ± 13.8 | 115.7 ± 15.0 | 116.4 ± 14.6 | 117.9 ± 14.3 | < 0.001 | |
| DBP V2 | 68.2 ± 9.3 | 70.8 ± 9.8 | 70.4 ± 9.9 | 72.2 ± 9.5 | < 0.001 | |
| Physical activity level | < 0.001 | |||||
| Low | 13.8 (129) | 9.9 (128) | 13.2 (58) | 10.0 (64) | ||
| Mod | 46.6 (581) | 45.1 (581) | 50.3 (221) | 47.0 (301) | ||
| High | 39.6 (580) | 45.0 (580) | 36.4 (160) | 43.0 (275) | ||
| Waist circumference, cm | ||||||
| Waist V1 | 87.7 ± 9.6 | 97.6 ± 12.2 | 89.0 ± 10.2 | 98.1 ± 11.9 | < 0.001 | |
| Waist V2 | 90.7 ± 10.7 | 99.6 ± 13.1 | 91.9 ± 11.6 | 99.7 ± 12.7 | < 0.001 | |
Notes: Data were represented with n, mean ± standard deviation or % (n) within each group. Continuous variables were compared using the Kruskal–Wallis test, whereas categorical variables were compared using the Chi-square test. P < 0.05 considered statistically significant.
Abbreviations: HOMA-IR, Homeostasis model assessment of insulin resistance; BMI, body mass index; HS, high school; SBP, systolic blood pressure; DBP, diastolic blood pressure; V1, visit 1; V2, visit 2.
In the primary analyses, Cox regression analyses to assess the associations of insomnia and IR with incident HTN over a mean follow-up period of 6 years, with the influence of covariates held constant. With sequential models, Model 1 only controlled for IR and insomnia; Model 2 added age, sex, and BMI; Model 3 further added education, alcohol use, cigarette use, physical activity level, ethnicity, waist circumference, baseline SBP, and baseline DBP. The results of the Cox regression analyses were presented as hazard ratios (HRs) and 95% confidence intervals (CIs). To examine whether insomnia modified the association between IR and incident HTN, an interaction term between IR and insomnia was added to the fully adjusted Cox regression model. The statistical significance of the interaction was evaluated using a Wald test. When a significant interaction was identified, a post-estimation linear combination analysis was performed to estimate the HR for IR among participants with insomnia.
We also conducted sex-stratified and age-stratified analyses to further investigate the associations of IR and insomnia with incident HTN. Participants were stratified by sex and by the median age of 42 years. Interaction terms were included to examine potential effects. The results are presented in a forest plot.
All statistical analyses were conducted in Stata 18.0, and all tests are two-sides, with significant P value 5%.
Results
Sample Characteristics
As shown in Table 1, a total of 3300 participants without baseline HTN were categorized into four groups: 28.2% (n = 932) were free of both insulin resistance and insomnia (the control group), 39.1% (n = 1289) had IR only, 13.3% (n = 439) had insomnia only, and 19.4% (n = 640) had comorbid IR and insomnia. Participants with insomnia, with or without IR, were slightly older than those in the control and IR only groups. Women predominated in all groups.
Cardiometabolic profiles differed markedly across the four groups. The incidence of HTN increased from 9.9% in the control group to 13.4% in the IR group, 14.1% in the insomnia group, and 19.7% in the comorbidity group (P < 0.001). HOMA-IR was substantially higher in participants with IR, particularly in those with comorbid insomnia, whereas HOMA-IR values were lowest in the control group. Similarly, BMI and waist circumference were highest in the IR and comorbidity groups and lowest in controls (P = 0.032). SBP, DBP, physical activity level, alcohol use, cigarette use, and ethnic background also differed significantly across the groups, while educational attainment and time between visits were comparable across the four groups.
IR, Insomnia and Incident HTN
Primary Analysis
In the primary analyses, we used Cox regression analysis to explore the relationship between IR, insomnia and incident HTN. Table 2 shows the adjusted HRs from three models. In the fully adjusted model, the comorbidity of IR and insomnia conferred a significantly elevated risk of incident HTN (HR, 1.39; 95% CI, 1.05–1.85). Notably, neither IR nor insomnia alone was associated with incident HTN, underscoring that the marked increase in HTN risk was specific to the comorbidity of IR and insomnia rather than IR or insomnia alone as an independent factor.
Table 2.
Effect Estimates from Cox Regression Models for the Association Between Insulin Resistance, Insomnia, and 6-Year Incident Hypertension in HCHS/SOL (2008–2017)
| Incident Hypertension | Model 1 | Model 2 | Model 3 | ||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | HR | 95% CI | ||
| (Group) | Normal | - | - | - | |||
| Insulin resistance | 1.38‡ | 1.07–1.78 | 1.37‡ | 1.05–1.79 | 1.06 | 0.80–1.39 | |
| Insomnia | 1.37 | 0.99–1.89 | 1.18 | 0.85–1.63 | 0.87 | 0.62–1.21 | |
| Comorbidity | 2.10* | 1.61–2.75 | 1.66* | 1.25–2.20 | 1.39‡ | 1.05–1.85 | |
Notes: Model 1 included insulin resistance and insomnia. Model 2 further controlled for age, BMI, sex. Model 3 further controlled for education, alcohol use, cigarette use, physical activity level, ethnicity, waist circumference, SBP, DBP. *P ≤ 0.001. †P < 0.01. ‡P < 0.05.
Abbreviations: HR, hazard ratio; 95% CI, 95% confidence intervals; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure.
Figure 2 presents the results of the fully adjusted Cox regression models for incident HTN in forest plots. In the sex-stratified analyses, the comorbidity of IR and insomnia was significantly associated with incident HTN among men (HR, 1.98; 95% CI, 1.10–3.56). In the age-stratified analyses, this association was statistically significant among participants younger than 42 years (HR, 2.12; 95% CI, 1.11–4.06).
Figure 2.

Sex-stratified and age-stratified analyses on association between insulin resistance, insomnia and incident hypertension from the HCHS/SOL. Cox regression model adjusted covariates for age, BMI, sex, education, alcohol use, cigarette use, physical activity level, ethnicity, waist circumference, SBP, DBP.
Interaction Analysis
To formally examine whether insomnia modified the association between IR and incident HTN, an interaction term (IR × insomnia) was introduced into the Cox regression model. As shown in Table 3, the interaction between IR and insomnia was statistically significant (HR for interaction, 1.52; 95% CI, 1.01–2.28; P = 0.045) after full adjustment. Post-estimation analysis using linear combination showed that among participants with insomnia, IR was associated with a 60% higher risk of incident HTN (HR, 1.60; 95% CI, 1.16–2.21; P = 0.004), whereas no significant association was observed among participants without insomnia (HR, 1.06; 95% CI, 0.80–1.39; P = 0.694).
Table 3.
Interaction Analysis Between Insulin Resistance and Insomnia on Incident Hypertension
| Analysis | HR (95% CI) | P value |
|---|---|---|
| Interaction term (insulin resistance × insomnia) | 1.52 (1.01–2.28) | 0.045 |
| Insulin resistance effect among participants without insomnia | 1.06 (0.80–1.39) | 0.694 |
| Insulin resistance effect among participants with insomnia* | 1.60 (1.16–2.21) | 0.004 |
Notes: *Estimated by post-estimation linear combination.
Abbreviations: HR hazard ratio; 95% CI, 95% confidence intervals.
Discussion
In this large community-based sample of Hispanic/Latino adults in the United States, neither IR nor insomnia alone was significantly associated with incident HTN after comprehensive adjustment. However, we observed a significant interaction between IR and insomnia, such that the increased risk of incident HTN associated with IR was evident only among participants with coexisting insomnia; this association appeared to be stronger in men and younger individuals. These findings suggest that insomnia may act as an effect modifier rather than an independent risk factor, unmasking or amplifying the metabolic and vascular consequences of IR.
Inconsistent with our study, previous longitudinal studies have reported positive associations between IR and incident HTN.10,29,30 Several methodological differences may explain this apparent discrepancy. First, unlike previous longitudinal studies using TyG or METS-IR,10,30 we employed HOMA-IR, a widely used and validated insulin-based measure that incorporates fasting insulin and glucose concentrations and correlates well with the HEC, the gold standard for assessing IR, to examine the association between IR and incident HTN.12 In contrast, the TyG index,31 and METS-IR32 may capture partly different metabolic dimensions and should not be regarded as directly interchangeable. Second, previous prospective studies often failed to adjust for sleep disorders including obstructive sleep apnea and insomnia, which are associated with both HTN and IR.13,33,34 Unmeasured confounding by sleep disorders may therefore have inflated prior estimates.29 Third, differences in study populations may also contribute to the discrepant findings.6–8,30,35 While a recent cross-sectional analysis study focused on the Hispanic /Latino population showed a significant linear association between IR and SBP and DBP,9 longitudinal data for this demographic remain scarce. Our study addresses this gap, though population-specific characteristics may also limit direct comparisons with non-Hispanic cohorts.
It was unexpected that no significant association was observed between insomnia and incident HTN in our study. While previous cross-sectional studies have consistently documented a significant relationship between insomnia and HTN, findings from longitudinal investigations remain inconsistent. On the one hand, several prospective studies have demonstrated that insomnia, or its characteristic symptoms, is associated with an increased risk of incident HTN.36,37 For instance, analyses from the HCHS/SOL previously identified a significant association between insomnia and incident HTN.13 On the other hand, some longitudinal studies have failed to detect any meaningful association between insomnia symptoms and incident HTN.38,39 Notably, one study even reported a reduced risk of HTN among older adults with insomnia.40 These discrepancies may arise from differences in population demographics, insufficient adjustment for lifestyle factors (eg, physical activity), or reliance on self-reported sleep duration.41 Additionally, the relatively long self-reported sleep duration in our study population may have masked the potential impact of shorter objective sleep duration, a factor that could further complicate the assessment of insomnia-related HTN risk.42
Notably, formal interaction analysis demonstrated that insomnia significantly modified the association between IR and incident HTN, with IR being associated with an increased HTN risk only among participants with insomnia. Our findings suggest that insomnia might exert a greater influence on HTN through modification of metabolic susceptibility rather than as a direct pressor effect. Mechanistically, several overlapping biological pathways may explain this interaction. First, both conditions have been linked to increased sympathetic nervous system (SNS) activity,5,43 a factor well-established as a key pathophysiological driver of HTN.44 Second, beyond SNS activation, insomnia and IR both promote systemic inflammation, a process frequently implicated in the initiation and progression of HTN.45 Notably, emerging research suggests a bidirectional interplay between IR and insomnia that may further amplify this risk. The inflammatory state, hyperadrenergic conditions, and endothelial dysfunction associated with IR may also play a role in perpetuating insomnia.46,47 Together, these shared and mutually reinforcing mechanisms provide a plausible biological explanation for why the association between IR and HTN became evident only in the presence of insomnia. In stratified analyses, the association appeared more evident among men and younger participants. Previous evidence suggests that sex hormones and sex-related differences in visceral adiposity and inflammatory responses may contribute to the observed pattern by sex,48,49 whereas age-related changes in renin–angiotensin–aldosterone system activity and hypothalamic–pituitary–adrenal axis responsiveness may partly explain the pattern observed across age groups.50,51
Our findings also generate several directions for future research and potential clinical and public health implications. Further studies are needed to elucidate the biological mechanisms through which insomnia may modify the association between IR and incident HTN. Replication in other ethnic and clinical populations is also needed to determine whether individuals with coexisting IR and insomnia consistently represent a subgroup at increased risk of HTN. For risk assessment, combined evaluation of IR and insomnia may improve identification of high-risk individuals, although formal testing of discrimination and reclassification is needed. For prevention and management, individuals with coexisting IR and insomnia may warrant closer blood pressure monitoring and targeted sleep interventions, such as cognitive behavioral therapy for insomnia. From a public health perspective, these findings support further evaluation of integrated sleep-health and metabolic-risk approaches for HTN prevention.
Key strengths of our study include the large, population-based Hispanic/Latino cohort, which provides much-needed longitudinal data for this understudied group, and the use of HOMA-IR, a robust surrogate measure suitable for epidemiological research. Despite these strengths, several limitations should also be acknowledged. First, no universally accepted HOMA-IR threshold exists for defining IR, and optimal cut-off values vary across populations.52 This inconsistency may lead to discrepancies with prior studies conducted in other populations or ethnic backgrounds, thereby limiting its practical application in clinical settings. Second, we used the WHIIRS to assess insomnia. Although the WHIIRS was developed from a multiethnic population of approximately 70,000 participants and has demonstrated high validity across different regions and ethnic groups,13 there still need to be cautious because it was originally developed and validated primarily in older women.27
Conclusion
In this longitudinal study of Hispanic/Latino adults, insomnia modified the association between IR and incident HTN. IR was associated with a higher risk of incident HTN only among participants with coexisting insomnia, whereas no significant association was observed among those without insomnia. These findings extend previous evidence that IR and insomnia are individually associated with HTN by showing that their coexistence may define a higher-risk phenotype. They suggest that insomnia may help identify a subgroup with increased susceptibility to HTN among individuals with IR. Further studies are needed to confirm the causal mechanisms and determine whether integrated metabolic and sleep-focused interventions can reduce HTN risk.
Funding Statement
Our work was supported by the National Natural Science Foundation of China (81900087, 82341249, 82470095), and the Brain Science and Brain-like Intelligence Technology-National Science and Technology Major Project (2025ZD0216400).
Data Sharing Statement
The data underlying this article are available in National Heart, Lung, and Blood Institute Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC), at https://biolincc.nhlbi.nih.gov/studies/hchssol/. The datasets were derived from sources in the public domain: Hispanic Community Health Study/Study of Latinos (HCHS/SOL), Clinical Trial URLs NCT02060344.
Ethics Approval and Informed Consent
This study used deidentified data from the HCHS/SOL study, which was approved by the institutional review boards of all participating institutions. All participants provided written informed consent. The present secondary analysis was approved by the Biomedical Ethics Committee of West China Hospital, Sichuan University (Approval No. 2023[2357]) and was conducted in accordance with the Declaration of Helsinki.
Author Contributions
Shuyao Wu and Yongming Wang share first authorship.
Y.M.W-Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Validation, Visualization, Writing – original draft. S.Y.W-Validation, Supervision, Writing – review & editing. W.Q.L-Validation, Supervision, Writing – review & editing. S.C.R- Validation, Supervision. X.D.T-Validation, Supervision, Writing – review & editing. Y.Z- Validation, Supervision, Writing – review & editing. R.R-Conceptualization, Validation, Supervision, Writing – review & editing. All authors contributed substantially to the conception or design of the study; data acquisition, analysis, or interpretation; and drafting or critical revision of the manuscript. All authors approved the final version, agreed to its submission to the selected journal, and accept accountability for all aspects of the work.
Disclosure
Dr Yongming Wang and Dr Rong Ren report support for the study from Ministry of Science and Technology of the People’s Republic of China, National Natural Science Foundation of China, during the conduct of the study.
The authors declare no further competing financial interests or personal relationships that could have appeared to influence the work reported in this article.
References
- 1.Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics-2023 update: a report from the American heart association. Circulation. 2023;147(8):e93–11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Gu A, Yue Y, Desai RP, et al. Racial and ethnic differences in antihypertensive medication use and blood pressure control among US adults with hypertension: the national health and nutrition examination survey, 2003 to 2012. Circ Cardiovasc Qual Outcomes. 2017;10(1). [DOI] [PubMed] [Google Scholar]
- 3.Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414(6865):782–787. doi: 10.1038/414782a [DOI] [PubMed] [Google Scholar]
- 4.Cooper SA, Whaley-Connell A, Habibi J, et al. Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol. 2007;293(4):H2009–H2023. [DOI] [PubMed] [Google Scholar]
- 5.Fossum E, Hoieggen A, Reims HM, et al. High screening blood pressure is related to sympathetic nervous system activity and insulin resistance in healthy young men. Blood Press. 2004;13(2):89–94. [DOI] [PubMed] [Google Scholar]
- 6.Guo Z, Guo X, Xu H, et al. Association between metabolic score for insulin resistance (METS-IR) and hypertension: a cross-sectional study based on NHANES 2007-2018. Lipids Health Dis. 2025;24(1):64. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Tan L, Liu Y, Liu J, et al. Association between insulin resistance and uncontrolled hypertension and arterial stiffness among US adults: a population-based study. Cardiovasc Diabetol. 2023;22(1). doi: 10.1186/s12933-023-02038-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Zeng J, Zhang T, Yang Y, et al. Association between a metabolic score for insulin resistance and hypertension: results from national health and nutrition examination survey 2007-2016 analyses. Front Endocrinol. 2024;15:1369600. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Quesada O, Claggett B, Rodriguez F, et al. Associations of insulin resistance with systolic and diastolic blood pressure: a study from the HCHS/SOL. Hypertension. 2021;78(3):716–725. doi: 10.1161/HYPERTENSIONAHA.120.16905 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Tsai KZ, Chu CC, Huang WC, et al. Prediction of various insulin resistance indices for the risk of hypertension among military young adults: the chief cohort study, 2014-2020. Cardiovasc Diabetol. 2024;23(1):141. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Zhang F, Yu Z. Mendelian randomization study on insulin resistance and risk of hypertension and cardiovascular disease. Sci Rep. 2024;14(1):6191. doi: 10.1038/s41598-023-46983-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Tahapary DL, Pratisthita LB, Fitri NA, et al. Challenges in the diagnosis of insulin resistance: focusing on the role of HOMA-IR and triglyceride/glucose index. Diabetes Metab Syndr. 2022;16(8):102581. [DOI] [PubMed] [Google Scholar]
- 13.Li X, Sotres-Alvarez D, Gallo LC, et al. Associations of sleep-disordered breathing and insomnia with incident hypertension and diabetes: the hispanic community health study/study of latinos. Am J Respir Crit Care Med. 2021;203(3):356–365. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Liu D, Yu C, Huang K, et al. The association between hypertension and insomnia: a bidirectional meta-analysis of prospective cohort studies. Int J Hypertens. 2022;2022(1):4476905. doi: 10.1155/2022/4476905 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Fernandez-Mendoza J, Vgontzas AN, Liao D, et al. Insomnia with objective short sleep duration and incident hypertension: the Penn State cohort. Hypertension. 2012;60(4):929–935. doi: 10.1161/HYPERTENSIONAHA.112.193268 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Buxton OM, Cain SW, O’connor SP, et al. Adverse metabolic consequences in humans of prolonged sleep restriction combined with circadian disruption. Sci Transl Med. 2012;4(129):129ra43. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Leproult R, Van Cauter E. Role of sleep and sleep loss in hormonal release and metabolism. Endocr Dev. 2010;17:11–21. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Wang X, Zhao C, Feng H, et al. Associations of insomnia with insulin resistance traits: a cross-sectional and Mendelian randomization study. J Clin Endocrinol Metab. 2023;108(8):e574–e582. [DOI] [PubMed] [Google Scholar]
- 19.Jain SK, Kahlon G, Morehead L, et al. The effect of sleep apnea and insomnia on blood levels of leptin, insulin resistance, IP-10, and hydrogen sulfide in type 2 diabetic patients. Metab Syndr Relat Disord. 2012;10(5):331–336. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Yamamoto N, Yamanaka G, Ishizawa K, et al. Insomnia increases insulin resistance and insulin secretion in elderly people. J Am Geriatr Soc. 2010;58(4):801–804. [DOI] [PubMed] [Google Scholar]
- 21.Wang Y, Lyu W, Feng X, et al. Associations of sleep-disordered breathing and insomnia with incident metabolic syndrome: the hispanic community health study/study of latinos. Nat Sci Sleep. 2025;17:2919–2931. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Sorlie PD, Aviles-Santa LM, Wassertheil-Smoller S, et al. Design and implementation of the hispanic community health study/study of latinos. Ann Epidemiol. 2010;20(8):629–641. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.LaVange LM, Kalsbeek WD, Sorlie PD, et al. Sample design and cohort selection in the hispanic community health Study/Study of latinos. Ann Epidemiol. 2010;20(8):642–649. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Westbrook PR, Levendowski DJ, Cvetinovic M, et al. Description and validation of the apnea risk evaluation system: a novel method to diagnose sleep apnea-hypopnea in the home. Chest. 2005;128(4):2166–2175. doi: 10.1378/chest.128.4.2166 [DOI] [PubMed] [Google Scholar]
- 25.Esteghamati A, Ashraf H, Khalilzadeh O, et al. Optimal cut-off of homeostasis model assessment of insulin resistance (HOMA-IR) for the diagnosis of metabolic syndrome: third national surveillance of risk factors of non-communicable diseases in Iran (SuRFNCD-2007). Nutr Metab. 2010;7(1):26. doi: 10.1186/1743-7075-7-26 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Levine DW, Kaplan RM, Kripke DF, et al. Factor structure and measurement invariance of the women’s health initiative insomnia rating scale. Psychol Assess. 2003;15(2):123–136. [DOI] [PubMed] [Google Scholar]
- 27.Levine DW, Lewis MA, Bowen DJ, et al. Reliability and validity of women’s health initiative insomnia rating scale. Psychol Assess. 2003;15(2):137–148. [DOI] [PubMed] [Google Scholar]
- 28.Bull FC, Maslin TS, Armstrong T. Global physical activity questionnaire (GPAQ): nine country reliability and validity study. J Phys Act Health. 2009;6(6):790–804. doi: 10.1123/jpah.6.6.790 [DOI] [PubMed] [Google Scholar]
- 29.Arshi B, Tohidi M, Derakhshan A, et al. Sex-specific relations between fasting insulin, insulin resistance and incident hypertension: 8.9 years follow-up in a Middle-Eastern population. J Hum Hypertens. 2015;29(4):260–267. doi: 10.1038/jhh.2014.70 [DOI] [PubMed] [Google Scholar]
- 30.Niu ZJ, Cui Y, Wei T, et al. The effect of insulin resistance in the association between obesity and hypertension incidence among Chinese middle-aged and older adults: data from China health and retirement longitudinal study (CHARLS). Front Public Health. 2024;12:1320918. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Khan SH, Sobia F, Niazi NK, et al. Metabolic clustering of risk factors: evaluation of triglyceride-glucose index (TyG index) for evaluation of insulin resistance. Diabetol Metab Syndr. 2018;10(1):74. doi: 10.1186/s13098-018-0376-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Aznar-Esquivel A, Gomez-Bernal F, Garcia-Gonzalez M, et al. The metabolic score for insulin resistance (METS-IR), a predictor of cardiovascular events, relates to disease activity in patients with rheumatoid arthritis. Diagnostics. 2025;15(7):861. doi: 10.3390/diagnostics15070861 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Marin JM, Agusti A, Villar I, et al. Association between treated and untreated obstructive sleep apnea and risk of hypertension. JAMA. 2012;307(20):2169–2176. doi: 10.1001/jama.2012.3418 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Zhou B, Yao Y, Wang Y, et al. Association between metabolic score for insulin Resistance (METS-IR) and risk of obstructive sleep apnea: analysis of NHANES database and a Chinese cohort. Nat Sci Sleep. 2025;17:607–620. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Liu H, Meng C, Wang Z, et al. Association of novel insulin resistance indices with blood pressure in new-onset hypertension and elevated blood pressure individuals: a cross-sectional study. Diabetes Metab Syndr Obes. 2023;16:3953–3965. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Lin CL, Liu TC, Lin FH, et al. Association between sleep disorders and hypertension in Taiwan: a nationwide population-based retrospective cohort study. J Hum Hypertens. 2017;31(3):220–224. doi: 10.1038/jhh.2016.55 [DOI] [PubMed] [Google Scholar]
- 37.Suka M, Yoshida K, Sugimori H. Persistent insomnia is a predictor of hypertension in Japanese male workers. J Occup Health. 2003;45(6):344–350. doi: 10.1539/joh.45.344 [DOI] [PubMed] [Google Scholar]
- 38.Zhang J, Lam SP, Li SX, et al. Long-term outcomes and predictors of chronic insomnia: a prospective study in Hong Kong Chinese adults. Sleep Med. 2012;13(5):455–462. [DOI] [PubMed] [Google Scholar]
- 39.Sivertsen B, Lallukka T, Salo P, et al. Insomnia as a risk factor for ill health: results from the large population-based prospective HUNT study in Norway. J Sleep Res. 2014;23(2):124–132. [DOI] [PubMed] [Google Scholar]
- 40.Phillips B, Buzkova P, Enright P. Insomnia did not predict incident hypertension in older adults in the cardiovascular health study. Sleep. 2009;32(1):65–72. doi: 10.5665/sleep/32.1.65 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Gerage AM, Benedetti TRB, Ritti-Dias RM, et al. Effectiveness of a behavior change program on physical activity and eating habits in patients with hypertension: a randomized controlled trial. J Phys Act Health. 2017;14(12):943–952. [DOI] [PubMed] [Google Scholar]
- 42.Lauderdale DS, Knutson KL, Yan LL, et al. Self-reported and measured sleep duration: how similar are they? Epidemiology. 2008;19(6):838–845. doi: 10.1097/EDE.0b013e318187a7b0 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Khan MS, Aouad R. The effects of insomnia and sleep loss on cardiovascular disease. Sleep Med Clin. 2017;12(2):167–177. doi: 10.1016/j.jsmc.2017.01.005 [DOI] [PubMed] [Google Scholar]
- 44.Bonnet MH. Evidence for the pathophysiology of insomnia. Sleep. 2009;32(4):441–442. doi: 10.1093/sleep/32.4.441 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Sakr HF, Sirasanagandla SR, Das S, et al. Insulin resistance and hypertension: mechanisms involved and modifying factors for effective glucose control. Biomedicines. 2023;11(8):2271. doi: 10.3390/biomedicines11082271 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Murray EC, Nosalski R, MacRitchie N, et al. Therapeutic targeting of inflammation in hypertension: from novel mechanisms to translational perspective. Cardiovasc Res. 2021;117(13):2589–2609. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Seravalle G, Mancia G, Grassi G. Sympathetic nervous system, sleep, and hypertension. Curr Hypertens Rep. 2018;20(9):74. doi: 10.1007/s11906-018-0874-y [DOI] [PubMed] [Google Scholar]
- 48.Marriott I, Bost KL, Huet-Hudson YM. Sexual dimorphism in expression of receptors for bacterial lipopolysaccharides in murine macrophages: a possible mechanism for gender-based differences in endotoxic shock susceptibility. J Reprod Immunol. 2006;71(1):12–27. doi: 10.1016/j.jri.2006.01.004 [DOI] [PubMed] [Google Scholar]
- 49.Singer K, Maley N, Mergian T, et al. Differences in hematopoietic stem cells contribute to sexually dimorphic inflammatory responses to high fat diet-induced obesity. J Biol Chem. 2015;290(21):13250–13262. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Tsunoda K, Abe K, Goto T, et al. Effect of age on the renin-angiotensin-aldosterone system in normal subjects: simultaneous measurement of active and inactive renin, renin substrate, and aldosterone in plasma. J Clin Endocrinol Metab. 1986;62(2):384–389. [DOI] [PubMed] [Google Scholar]
- 51.Kudielka BM, Buske-Kirschbaum A, Hellhammer DH, et al. HPA axis responses to laboratory psychosocial stress in healthy elderly adults, younger adults, and children: impact of age and gender. Psychoneuroendocrinology. 2004;29(1):83–98. doi: 10.1016/S0306-4530(02)00146-4 [DOI] [PubMed] [Google Scholar]
- 52.Gayoso-Diz P, Otero-Gonzalez A, Rodriguez-Alvarez MX, et al. Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study. BMC Endocr Disord. 2013;13(1):47. doi: 10.1186/1472-6823-13-47 [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The data underlying this article are available in National Heart, Lung, and Blood Institute Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC), at https://biolincc.nhlbi.nih.gov/studies/hchssol/. The datasets were derived from sources in the public domain: Hispanic Community Health Study/Study of Latinos (HCHS/SOL), Clinical Trial URLs NCT02060344.
